| Literature DB >> 32023468 |
Jayne Louise Wilson1, Thomas Nägele2, Monika Linke1, Florian Demel1, Stephanie D Fritsch1, Hannah Katharina Mayr1, Zhengnan Cai3, Karl Katholnig1, Xiaoliang Sun4, Lena Fragner5, Anne Miller6, Arvand Haschemi6, Alexandra Popa7, Andreas Bergthaler7, Markus Hengstschläger1, Thomas Weichhart8, Wolfram Weckwerth9.
Abstract
Mechanistic or mammalian target of rapamycin complex 1 (mTORC1) is an important regulator of effector functions, proliferation, and cellular metabolism in macrophages. The biochemical processes that are controlled by mTORC1 are still being defined. Here, we demonstrate that integrative multiomics in conjunction with a data-driven inverse modeling approach, termed COVRECON, identifies a biochemical node that influences overall metabolic profiles and reactions of mTORC1-dependent macrophage metabolism. Using a combined approach of metabolomics, proteomics, mRNA expression analysis, and enzymatic activity measurements, we demonstrate that Tsc2, a negative regulator of mTORC1 signaling, critically influences the cellular activity of macrophages by regulating the enzyme phosphoglycerate dehydrogenase (Phgdh) in an mTORC1-dependent manner. More generally, while lipopolysaccharide (LPS)-stimulated macrophages repress Phgdh activity, IL-4-stimulated macrophages increase the activity of the enzyme required for the expression of key anti-inflammatory molecules and macrophage proliferation. Thus, we identify Phgdh as a metabolic checkpoint of M2 macrophages.Entities:
Keywords: Phgdh; Tsc2; biochemical Jacobian; cancer; mTOR; macrophage polarization; macrophage proliferation; metabolic modeling; metabolomics; serine/glycine pathway; tumor-associated macrophages
Year: 2020 PMID: 32023468 PMCID: PMC7003064 DOI: 10.1016/j.celrep.2020.01.011
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423
Figure 1COVRECON Strategy
From the integrative analysis of metabolites and proteins, covariance matrices are formed (COV), which give rise to metabolite and protein correlation network analyses. To allow for inverse modeling of biochemical regulation from metabolomics covariance data, a metabolic reconstruction and pathway reduction from available genome sequences is performed (RECON). The predicted biochemical perturbations are validated with proteomics data and enzymatic activity measurements.
Figure 2Differential Jacobian Identifies α-Ketoglutarate/Glutamate Alterations in Tsc2-Deficient Macrophages
(A) Principal component analysis (PCA) of the metabolite data revealing a separation between the Tsc2fl/fl and Tsc2fl/flLyz2-Cre genotypes (87.97% total variance covered on PC1-PC3) (Data S1). The biological variance of the independent biological replicates per cell type is visible, which is further exploited first for the calculation of the Covariance matrix COV and subsequently for the Jacobian matrix JAC using the stochastic Lyapunov matrix Equation 1 (for further details see Weckwerth, 2019)
(B) Simplified biochemical interaction network adjusted to the measured metabolites (for further details see text and the complete model in Data S1).
(C) Differential Jacobian matrix of Tsc2fl/fl and Tsc2fl/flLyz2-Cre BMDMs derived from covariance data from the metabolomics datasets. All entries represent median values of 103 calculations normalized to the square of interquartile distance. df and dM characterize the entries of the Jacobian matrix and refer to Equation 2. The greatest perturbation was identified as the Jacobian entry , pointing to 3 potential reactions in the underlying biochemical network (B).
Figure 3Tsc2-mTORC1 Regulate Phgdh in Macrophages
(A) List of the 10 most significantly altered proteins in Tsc2fl/flLyz2-Cre (KO) versus Tsc2fl/fl (Ctrl) BMDMs. Fold change is displayed as log2∗10 of Tsc2fl/flLyz2-Cre versus Tsc2fl/fl. Data are presented as mean ± SEM (n = 4).
(B) Representative immunoblots of CSF1-deprived Tsc2fl/fl and Tsc2fl/flLyz2-Cre BMDMs treated for 18 h with rapamycin (100 nM) or solvent control and hybridized with the indicated antibodies.
(C) Total RNA was isolated from Tsc2fl/fl and Tsc2fl/flLyz2-Cre BMDMs treated for 18 h with rapamycin (100 nM) or solvent control. Expression levels of the indicated mRNAs were determined by qRT-PCR and normalized to β-actin. Gene expression is presented as fold change versus unstimulated Tsc2fl/fl cells. Data are presented as mean ± SEM. ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 4Phgdh Expression and Activity Is a Signature of M2 Macrophages
(A and B) Total RNA was isolated from unstimulated (Ctrl), LPS-stimulated (100 ng/mL), or IL-4-stimulated (10 ng/mL) wild-type BMDMs after incubation for 24 h (A) or 0, 8, and 16 h (B). Expression levels of the indicated mRNAs were determined by qRT-PCR and normalized to β-actin. Gene expression is presented as fold change versus unstimulated cells. Data are presented as mean ± SEM (n = 4).
(C) BMDMs were stimulated for 24 h with IL-4 (10 ng/mL) or solvent control. Whole-cell lysates were analyzed by immunoblotting using the indicated antibodies. Data are representative of 3 independent experiments.
(D) Phgdh enzyme activity was determined in protein lysates from wild-type BMDMs stimulated for 24 h with LPS (100 ng/mL) or IL-4 (10 ng/mL) in RPMI-1640 medium (Teknova) with or without glucose, serine and glycine. Phgdh activity was measured by the formation of NADH over time in a buffer containing NAD and the substrate 3-phospho-D-glycerate. Data are presented as mean ± SEM (n = 3–4). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
Figure 5Phgdh Is Required for M2 Polarization of Macrophages
(A) Phgdh enzyme activity was determined in protein lysates from wild-type BMDMs stimulated for 24 h with IL-4 (10 ng/mL) in RPMI-1640 medium (Teknova) supplemented with glucose, serine, and glycine. Phgdh activity was measured by the formation of NADH over time in a reaction buffer containing NAD and the substrate 3-phospho-D-glycerate. To analyze the activity of the Phgdh inhibitors, 30 μM CBR-5884, 25 μM NCT-503, or solvent control (Ctrl) were added directly to the reaction buffer immediately prior to starting the activity assay. Data are presented as mean ± SEM (n = 4).
(B and C) Total RNA was isolated from unstimulated wild-type BMDMs or wild-type BMDMs stimulated for 24 h with IL-4 (10 ng/mL) in the presence or absence of CBR-5884 (30 μM) or NCT-503 (25 μM). Gene expression levels of the indicated mRNAs were determined by qRT-PCR and normalized to β-actin. Inhibition of PHGDH reduced the expression of M2 signature genes Arg1, Retnla, and Chil3. Gene expression is presented as fold change versus untreated cells. Data are presented as mean ± SEM (n = 4).
(D–F) IL-10 (D), TNF-α (E), and IL-1β (F) production by unstimulated wild-type BMDMs (Ctrl), or wild-type BMDMs stimulated for 24 h with LPS (100 ng/mL) in the presence or absence of CBR-5884 (30 μM), was determined in RPMI-1640 medium (Teknova) with or without glucose, serine, and glycine. Data are presented as mean ± SEM (n = 4). ∗p < 0.05; ∗∗p < 0.01.
Figure 6M2 Polarization of Macrophages Is Independent of Serine and Glycine in the Medium
Total RNA was isolated from unstimulated (Ctrl) or IL-4-stimulated (10 ng/mL) wild-type BMDMs after incubation for 24 h in RPMI-1640 medium (Teknova) with or without glucose, serine, and glycine. mRNA expression levels of Arg1 (A), Retnla (B), Chil3 (C), and Igf1 (D) were determined by qRT-PCR and normalized to β-actin. Gene expression is presented as fold change versus unstimulated cells. Data are presented as mean ± SEM (n = 4).
Figure 7Cell Proliferation Is a Signature of Phgdh Activity in M2-Polarized Tsc2-Deficient Macrophages
(A) Volcano plot of differentially expressed genes in IL-4 stimulated macrophages after treatment with CBR-5884.
(B) Top enriched GO terms of macrophages treated with IL-4 or IL-4 and the Phgdh inhibitor CBR-5884 (30 μM).
(C) Representative cell-cycle analysis of Tsc2fl/fl (n = 3) and Tsc2fl/flLyz2-Cre (n = 4) BMDMs treated for 24 h with CBR-5884 (30 μM; +CBR) or solvent control (Ctrl) and stained with EdU/7-AAD.
(D) Quantification of the cell-cycle analysis shown in (C). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Hsp90 | Cell Signaling | Cat#4877; RRID: |
| Anti-Arginase-1 Antibody | Sigma-Aldrich | Cat# ABS535; RRID: |
| Anti-α-Tubulin Mouse mAb (DM1A) | Calbiochem | Cat#CP06; RRID: |
| Goat anti-Rabbit IgA cross-adsorbed Antibody HRP Conjugated | Bethyl Laboratories | Cat# A120-209P, RRID: |
| Anti-PHGDH antibody produced in rabbit | Sigma Aldrich Prestige Antibodies | Cat#HPA021241; RRID: |
| L-929-conditioned supernatant | This paper | N/A |
| Bone marrow-derived macrophages (BMDMs) | This paper: C57BL/6J, | N/A |
| Recombinant Murine M-CSF | Peprotech | Cat#315-02 |
| Endoproteinase Lys-C | Biolabs | Cat# P8109S |
| Urea | Sigma-Aldrich | Cat# 57-13-6 |
| Ammonium bicarbonate | Sigma-Aldrich | Cat#1066-33-7 |
| Ammonium acetate | Sigma-Aldrich | Cat#631-61-8 |
| Dithiothreitol (DTT) | Sigma-Aldrich | Cat#16096-97-2 |
| IAA | Sigma-Aldrich | Cat#144-48-9 |
| Acetonitrile | Merck | Cat#75-05-8 |
| SPEC C18 | Varian | Cat#A59603 |
| Graphite | Thermo-Scientific- Pierce | Cat#88302 |
| Recombinant Murine IL-4 | Peprotech | Cat#214-14 |
| Lipopolysaccharides from | Sigma Aldrich | Cat#L2630 |
| β-Nicotinamide adenine dinucleotide sodium salt (NAD) | Sigma Aldrich | Cat#N0632-1G |
| D-(−)-3-Phosphoglyceric acid disodium salt | Sigma Aldrich | Cat#P8877 |
| CBR-5884 | Axon Medchem | Cat#Axon 2585 |
| NCT-503 | Sigma Aldrich | Cat#SML1659 |
| InSolution Rapamycin | Calbiochem | Cat#553211 |
| cOmplete, EDTA-free Protease Inhibitor Cocktail | Sigma-Aldrich | Cat# COEDTAF-RO Roche |
| Aprotinin Protease Inhibitor | Thermo Scientific | Cat# 78432 |
| Leupeptin Protease Inhibitor | Thermo Scientific | Cat# 78435 |
| Benzamidine | Sigma-Aldrich | Cat# B6506 |
| Trypsin inhibitor | Merck | Cat |
| PMSF | Sigma Aldrich | Cat# P7626 |
| TRI Reagent® | Sigma Aldrich | Cat#T9424 |
| RNase A | Merck | Cat# R6513 |
| 7-Aminoactinomycin D | Sigma Aldrich | Cat#A9400 |
| ELISA MAX Deluxe Set Mouse IL-10 | BioLegend | Cat#431414 |
| ELISA MAX Deluxe Set Mouse IL-1β | BioLegend | Cat#432604 |
| ELISA MAX Deluxe Set Mouse TNF-α | BioLegend | Cat#430904 |
| Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit | Invitrogen | Cat#C10419 |
| GoScript Reverse Transcription Mix, Oligo(dT) | Promega | Cat#A2791 |
| GoTaq® qPCR Master Mix | Promega | Cat#A6001 |
| RNeasy Plus Micro Kit (50) | QIAGEN | Cat#74034 |
| RNA 6000 Nano Kit | Agilent Technologies | Cat#5067-1511 |
| NEBNext® Ultra Directional RNA Library Prep Kit for Illumina® | New England Biolabs | Cat#E7420 |
| Agilent High Sensitivity DNA Kit | Agilent Technologies | Cat#5067-4626 |
| Qubit dsDNA HS Assay Kit | Invitrogen | Cat#Q32851 |
| Mass spectrometry proteomics data | This paper | Proteomexchange ( |
| RNA-Sequencing data | This paper | Gene Expression Omnibus: |
| NCTC clone 929 cell line, CLS | NA | Cat# 400260/p757_L-929, RRID:CVCL_0462 |
| Mouse: C57BL/6J | Department of Laboratory Animal Science & Genetics, Medical University of Vienna | N/A |
| Mouse: | N/A | |
| Mouse: | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| β | This paper | N/A |
| β | This paper | N/A |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| This paper | N/A | |
| MaxQuant | Max Planck Institute of Biochemistry, Germany; | RRID: |
| Microsoft Excel | Microsoft | RRID: |
| MATLAB (v8.4.0 R2014b) | MathWorks | RRID: |
| COVAIN Toolbox - Wolfram | URL | |
| R | The R Project for Statistical Computing | URL |
| GraphPad Prism | GraphPad | RRID: |
| Bowtie | John Hopkins University, USA | RRID: |
| Cufflinks | Cole Trapnell Lab, University of Washington, USA | RRID: |
| Cytoscape (v3.6.0) | The Cytoscape Consortium | RRID: |
| KEGG | Kanehisa Laboratory, Kyoto University, Japan | RRID: |
| Gene Ontology | The Gene Ontology Consortium | RRID: |
| Reactome | The Reactome Group | RRID: |
| WikiPathways | RRID: | |
| Tophat | John Hopkins University, Center for Computational Biology, USA | RRID: |
| ClueGO (v2.3.3) | Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, France | RRID: |
| ProteomeXchange | The ProteomeXchange Consortium, | RRID: |
| PRIDE | The European Bioinformatics Institute (EMBL-EBI), UK | RRID: |